Anna Minchom

机构：Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Cancer Research UK, Institute of Cancer Research, Royal Marsden Hospital · ORCID：0000-0002-9339-7101

发表论文 309 篇 · 总被引 2382 次 · h-index 27

代表论文

A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR) (2026 · The Lancet Oncology · 被引 2)
Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma (2026 · Clinical Cancer Research · 被引 1)
Supplementary Table 5 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma (2026)
Supplementary Figure 4. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma (2026)
Supplementary Table 4 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma (2026)
Data from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma (2026)